Wide Ranks

CDTTW

0.0155

Top Statistics
Market Cap 0.0000 Forward PE 0.0000 Revenue Growth 0.00 %
Current Ratio 0.56 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 433000 Total Cash Per Share 0.0050 Total Debt 1 M
Total Debt To Equity Current Ratio 0.56 Book Value Per Share -0.0060
All Measures
Message Board Id finmb_1772079937 City San Diego Uuid efa815cc-dbd7-3007-b8f9-d5156d350c38
Previous Close 0.0216 Book Value -0.0060 Beta 2.12
Total Debt 1 M Volume 13365 Fifty Two Week Low 0.0100
Total Cash Per Share 0.0050 Max Age 86400 Sand P52 Week Change 0.3133
Net Income To Common -5692000 Trailing Peg Ratio None Total Cash 433000
Trailing PE 0.0000 Regular Market Previous Close 0.0216 Target Low Price 0.0000
Gmt Off Set Milliseconds -18000000 Open 0.0100 Dividend Yield 0.00 %
State CA Return On Assets -3.22 Time Zone Short Name EST
Day Low 0.0100 Address1 4995 Murphy Canyon Road Target High Price 0.0000
Price Hint 4 Website https://www.conduitpharma.com Forward Eps 0.0000
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 21.70 %
Is_sp_500 False Regular Market Day High 0.0215 Profit Margins 0.00 %
Fifty Two Week High 0.0215 Day High 0.0215 Regular Market Open 0.0100
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Operating Cashflow -9197000 Currency USD Time Zone Full Name America/New_York
Is_nasdaq_100 False Market Cap 0.0000 Zip 92123
Quote Type EQUITY Industry Biotechnology Long Name Conduit Pharmaceuticals Inc.
Regular Market Day Low 0.0100 Current Price 0.0155 Address2 Suite 300
Financial Currency USD Current Ratio 0.56 Industry Disp Biotechnology
Country United States Float Shares 53 M Forward PE 0.0000
Regular Market Volume 13365 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.

Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

The company was founded in 2019 and is based in San Diego, California.

Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.